The stock of Ignyta Inc (NASDAQ:RXDX) is a huge mover today! About 135,699 shares traded hands. Ignyta Inc (NASDAQ:RXDX) has declined 15.38% since April 14, 2016 and is downtrending. It has underperformed by 20.06% the S&P500.
The move comes after 8 months negative chart setup for the $267.62 million company. It was reported on Nov, 16 by Barchart.com. We have $5.79 PT which if reached, will make NASDAQ:RXDX worth $26.76M less.
Ignyta Inc (NASDAQ:RXDX) Ratings Coverage
Out of 6 analysts covering Ignyta (NASDAQ:RXDX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ignyta has been the topic of 10 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock of Ignyta Inc (NASDAQ:RXDX) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. On Tuesday, March 15 the stock rating was maintained by Credit Suisse with “Outperform”. JP Morgan initiated Ignyta Inc (NASDAQ:RXDX) rating on Thursday, June 23. JP Morgan has “Overweight” rating and $15 price target. As per Monday, October 26, the company rating was initiated by Cantor Fitzgerald. The rating was initiated by Canaccord Genuity with “Buy” on Monday, October 26. As per Friday, October 23, the company rating was initiated by Jefferies. The rating was initiated by Cantor Fitzgerald on Tuesday, November 10 with “Buy”. The rating was maintained by Piper Jaffray on Wednesday, August 12 with “Overweight”.
According to Zacks Investment Research, “Ignyta, Inc. is a biotechnology company. It develops precision medicine with integrated Rx/Dx solutions for cancer patients. The company focuses on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases. Ignyta, Inc. is based in San Diego, California.”
Insitutional Activity: The institutional sentiment increased to 2.87 in 2016 Q2. Its up 1.47, from 1.4 in 2016Q1. The ratio improved, as 6 funds sold all Ignyta Inc shares owned while 9 reduced positions. 11 funds bought stakes while 32 increased positions. They now own 24.37 million shares or 38.14% more from 17.64 million shares in 2016Q1.
Blackrock Limited Liability reported 93,702 shares or 0% of all its holdings. Credit Suisse Ag owns 25,096 shares or 0% of their US portfolio. Moreover, Voya Investment Mgmt Limited Liability Corporation has 0% invested in Ignyta Inc (NASDAQ:RXDX) for 14,152 shares. Armistice Cap Limited Liability Corp has 1.56M shares for 3.21% of their US portfolio. D E Shaw & Co owns 24,867 shares or 0% of their US portfolio. Tfs Capital Ltd Com owns 65,576 shares or 0.07% of their US portfolio. State Street holds 0% of its portfolio in Ignyta Inc (NASDAQ:RXDX) for 316,427 shares. Alliancebernstein Ltd Partnership accumulated 20,300 shares or 0% of the stock. Aqr Management Limited Liability Corp accumulated 29,840 shares or 0% of the stock. California State Teachers Retirement System holds 0% or 61,811 shares in its portfolio. Tiaa Cref Mngmt Ltd accumulated 127,641 shares or 0% of the stock. Bnp Paribas Arbitrage Sa holds 0% or 1,148 shares in its portfolio. California Pub Employees Retirement holds 0% or 61,800 shares in its portfolio. Legal And General Grp Public Limited Company last reported 2,975 shares in the company. National Bank Of America Corporation De last reported 0% of its portfolio in the stock.
More news for Ignyta Inc (NASDAQ:RXDX) were recently published by: Fool.com, which released: “Why Ignyta Inc. Shares Are Skyrocketing Higher” on June 01, 2015. Businesswire.com‘s article titled: “Ignyta Announces Initiation of STARTRK â€œNext Generationâ€ Phase 1/1b Pediatric …” and published on December 09, 2015 is yet another important article.
RXDX Company Profile
Prometheus RxDx Corp., incorporated in June 2009, is a wholly owned subsidiary of Prometheus Laboratories Inc. The Firm is engaged in the development and commercialization of pharmaceutical and diagnostic products that enable physicians to provide individualized patient care. It focuses on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology. It operates in two divisions: the pharmaceutical products segment that markets and sells prescription drugs, and the diagnostic testing services segment, which includes specific immunoassays to detect and differentiate diseases, pharmacogenetic testing and drug metabolite monitoring. The pharmaceutical products for gastrointestinal diseases and disorders includes ENTOCORT EC (budesonide) Capsules, which is indicated for the treatment of mild to moderate active Crohnâ€™s disease involving the ileum and/or the ascending colon, and LOTRONEX (alosetron hydrochloride) Tablets, for use in female patients with severe diarrhea-predominant irritable bowel syndrome (IBS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.